Effect of influenza vaccination on risk of COVID-19 – A prospective cohort study of 46,000 health care workers

Jonas Henrik Kristensen¹,²,¹⁶ M.D., Rasmus Bo Hasselbalch¹,²,¹⁶ M.D., Mia Pries-Heje³,¹⁶ M.D., Pernille Brok Nielsen¹,²,¹⁶ M.D., Andreas Dehlbæk Knudsen³,⁴,¹⁶ M.D., Kamille Fogh¹,²,¹⁶ M.D., Jakob Boesgaard Norsk¹,²,¹⁶ M.D., Aleksander Eiken⁶,¹⁶ M.D., Ove Andersen⁵,¹⁶ D.M.Sc., Thea Kølsen Fischer⁶,¹⁷ D.M.Sc., Claus Antonio Juul Jensen⁷,¹⁶ M.D., Christian Torp-Pedersen⁶,¹⁷ D.M.Sc., Jørgen Rungby⁸,¹⁶ D.M.Sc., Sisse Bolm Ditlev¹³,¹⁶ Ph.D., Ida Hageman⁹,¹⁶ M.D., Rasmus Møgelvang³,¹⁶ Ph.D., Mikkel Gybel-Brask¹²,¹⁶ M.D., Ram Benny Dessau¹⁵,¹⁸ Ph.D., Erik Sørensen M.D.¹²,¹⁶, Lene Harritshøj¹²,¹⁶ Ph.D., Fredrik Folke¹,¹⁰,¹⁶ Ph.D., Maria Elizabeth Engel Møller¹¹ M.D., Thomas Benfield¹¹,¹⁶ M.D., Henrik Ullum¹⁴ Ph.D., Charlotte Sværke Jørgensen Ph.D.¹⁴, Sisse Rye Ostrowski, D.M.Sc.¹²,¹⁶, Susanne Dam Nielsen⁶,¹⁶ D.M.Sc., Henning Bundgaard¹,¹⁶ D.M.Sc.*, and Kasper Iversen¹,²,¹⁶ D.M.Sc.*

*Shared last authorship

1 Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls vej 1, 2730 Herlev, Denmark
2 Department of Emergency Medicine, Copenhagen University Hospital - Herlev and Gentofte, Borgmester Ib Juuls vej 1, 2730 Herlev, Denmark
3 Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
4 Department of Infectious Disease, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
5 Department of Emergency and Department of Clinical Research, Copenhagen University Hospital – Amager og Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark

6 Department of Clinical Research, Copenhagen University Hospital – Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark

7 Department of Clinical Biochemistry, Copenhagen University Hospital – Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark

8 Department of Endocrinology and Copenhagen Center for Translational Research, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark

9 Mental Health Services - The Capital Region of Denmark, Kristineberg 3, 2100 Copenhagen, Denmark

10 Copenhagen University Hospital - Copenhagen Emergency Medical Services, Telegrafvej 5A, Stairway 2, 2750 Ballerup, Denmark

11 Department of Infectious Disease, Copenhagen University Hospital - Amager and Hvidovre, Kettegaard Alle 30, 2650 Hvidovre, Denmark

12 Department of Clinical Immunology, Copenhagen University Hospital – Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

13 Department of Pulmonary Medicine and Copenhagen Center for Translational Research, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark

14 Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark
Summary

This cohort study of 46,112 health care workers examined the effect of influenza vaccination on hospitalization and symptoms due to COVID-19, and development of antibodies against SARS-CoV-2. Influenza vaccination had no effect on the specified outcomes.

Corresponding author
Dr. Jonas Henrik Kristensen, M.D., Ph.D. student
Department of Emergency Care and Department of Cardiology
Faculty of Health and Medical Sciences
University of Copenhagen
Copenhagen University Hospital – Herlev & Gentofte
Borgmester Ib Juuls Vej 1, 2730 Herlev, Denmark.

Email: Jonas.henrik.kristensen@regionh.dk
Ph +45 38 68 66 42
Abstract

The purpose of this study was to assess if influenza vaccination has an impact on the risk of COVID-19. A cohort of 46,112 health care workers were tested for antibodies against SARS-CoV-2 and filled in a survey on COVID-19 symptoms, hospitalization, and influenza vaccination. The RR of hospitalization due to SARS-CoV-2 for influenza vaccinated compared with unvaccinated participants was 1.00 for the seasonal vaccination in 2019/2020 (CI 0.56-1.78, p=1.00). Likewise, no clinical effect of influenza vaccination on development of antibodies against SARS-CoV-2 was found. The present findings indicate that influenza vaccination does not affect the risk of SARS-CoV-2 infection or COVID-19.

Keywords

COVID-19, health care workers, SARS-CoV-2, influenza vaccination, cohort study, hospitalization, seroprevalence
Background

There is an intense search for preventive measures and effective treatments of Corona Virus Disease 2019 (COVID-19). Approximately 300 million cases have been confirmed and more than five million have died [1].

It has been suggested that immunity against influenza virus may cause some protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which has led to recommendation of influenza vaccination as a preventive measure against COVID-19[2]. This idea was supported by similarities in host-immune responses to the two viruses.

However, there has also been concerns of an interaction between influenza vaccination and the risk of SARS-CoV-2 infection. Such concerns may spread fast and affect the public support for recommendations of the authorities [3]. Studies are needed to address such concerns.

In Denmark influenza vaccination was offered to health care workers (HCW) from October 1, 2018, to March 1, 2019, and from November 1, 2019, to March 1, 2020.

We examined if influenza vaccination altered the risk of SARS-CoV-2 infection and clinical outcomes of COVID-19.

Methods

In this prospective cohort study repeated measurements of antibodies against SARS-CoV-2 were offered to HCW at hospitals, specialized health care institutions, and in the primary sector in the Capital Region and the Region of Zealand in Denmark (estimated total of 60,681 HCW)[4].

Antibody screening was offered three times during the COVID-19 pandemic in 2020. The first screening was offered April 15– May 7, the second screening was offered June 2–10, and the last screening was offered September 30– October 7. Participants in the second and third screening rounds were not required to have participated previously.
Each hospital department established a dedicated blood sampling station where staff could have a blood sample drawn. A contact person was appointed at each department for local organization and recruitment. Pop-up blood sampling stations were organized for HCW working at psychiatric institutions, specialized health care institutions and hospital departments, where local organization of blood sampling was not possible. HCW in the primary sector were able to draw blood samples at their clinic or drop by the pop-up blood sampling stations during -or after- regular work hours. Information on how to participate was disseminated by local contact persons, by heads of departments, and by mail to each HCW’s email at the Danish, governmental, personal, password-protected system, e-Boks.

Participants were encouraged to answer an online questionnaire regarding hospitalization and symptoms due to COVID-19, other health-related issues and influenza vaccination. The questionnaire was accessed either via a link sent to their e-Boks or a QR code handed out at the blood sampling clinics. Questionnaire data were collected and managed using Research Electronic Data Capture, a secure, web-based, electronic data capture tool, hosted at the Capital Region's server [5,6]. The questionnaire of each participant was linked with antibody test results by the central personal registration (CPR) number which is used for safe identification of individuals living in Denmark.

The enzyme-linked immunosorbent assay from Wantai (Beijing, China) was applied for detection of antibodies against SARS-CoV-2 (total immunoglobulin G, M and A) according to the manufacturer’s instructions. Internal validations with a sensitivity of 96.7% and a specificity of 99.5 % were in accordance with the package insert (sensitivity 94.5% and a specificity of 100%)[7].

The primary outcome was hospitalization due to COVID-19. The secondary outcomes were infection with SARS-CoV-2 as measured by serology, and symptomatic COVID-19.

This study was presented to the scientific ethics committee of the Capital Region, who concluded that the study did not require a scientific ethical approval (J.nr-H-20026288). The study was
registered with the Danish Data Protection Authorities (P-2020-361) and the protocol is registered at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04346186).

Further information on the study setup and the assay has previously been outlined[8,9]. For information on the vaccines in use against influenza in 2019/2020 and 2018/2019 in Denmark see appendix p.1.

**Statistical analyses**

Continuous data were presented as median (interquartile range (IQR)) according to non-normality and differences were explored using Wilcoxon rank sum test. Dichotomous data were examined by Fisher’s exact test and categorical data with more than two levels were examined by Pearson’s chi-squared test. Effects of influenza vaccination were explored by risk ratios (RRs). Adjusted odds ratios (OR) were calculated by logistic regression controlling for significant differences in baseline characteristics; age ≥ 65 years, sex, ever smoker, unhealthy alcohol consumption as defined in table 1, diabetes, immune deficiency, lung-, heart-, or kidney disease, patient contact, working at COVID-19 wards, and educational level as defined in table 1. Logistic regression models were examined for goodness of fit by Hosmer-Lemeshow-test (hl-test)[10]. RRs and ORs were presented with 95% confidence intervals (CI) calculated using the normal approximation (Wald). A p-value of less than 0.05 (two-sided) was considered significant. Calculations were done using R (version3.6.1).

**Results**

Of an estimated 60,681 HCW, 48,709 HCW filled in the questionnaire and consented to having their information used. The response rate was 75.99%. Information on influenza vaccination was available for 46,112 participants, who constituted the cohort of the current study. Information on influenza vaccination and antibody status against SARS-CoV-2 was available for 34,366 and 35,168 participants in the seasons 2018/2019 and 2019/2020, respectively. Information on hospitalization and symptomatic infection was filled in by 3,379 participants with previous SARS-CoV-2
infection. Baseline characteristics are shown in Table 1. The influenza vaccinated participants were older, more educated, and had more comorbidities than the unvaccinated participants.

Study outcomes are presented in table 2. When the risk of hospitalization due to SARS-CoV-2 for influenza vaccinated participants was compared with the risk for unvaccinated participants, a RR of 1.00 and a RR of 1.01 were found for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 0.56-1.78, p=1.00, and CI 0.55-1.87, p=1.00). The RRs of symptomatic COVID-19 were 1.03 and 1.02 for vaccinated compared with unvaccinated participants for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 1.01-1.06, p=0.017, and CI 1.00-1.05, p=0.108). The RRs of developing antibodies to SARS-CoV-2 in participants vaccinated against influenza virus were 1.01 and 0.93 compared with unvaccinated participants for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 0.93-1.10, p=0.779, and CI 0.85-1.02, p=0.145).

Adjusted ORs for hospitalization of 0.91 and 0.89 were found when comparing influenza vaccinated with unvaccinated participants for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 0.49-1.67, p=0.752, h-test p=0.831, and CI 0.47-1.70, p=0.723, h-test p=0.844).

Adjusted ORs for symptomatic COVID-19 of 1.24 and 1.16 were found for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 0.97-1.59, p=0.085, h-test p=0.215 and CI 0.89-1.51, p=0.267, h-test p=0.806). Adjusted ORs for developing antibodies against SARS-CoV-2 of 1.06 and 1.00 were found for the seasonal vaccination in 2019/2020 and 2018/2019, respectively (CI 0.97-1.17, p=0.213, h-test p=0.482, and CI 0.90-1.10, p=0.953, h-test p=0.411).

In a subgroup analysis of participants aged ≥65 years (n=1,841) the RRs of developing antibodies against SARS-CoV-2 were 0.93 and 0.99 for influenza vaccinated compared with unvaccinated participants for the seasonal vaccination in 2019/2022 and 2018/2019, respectively (CI 0.55-1.57, p=0.889, and CI 0.58-1.68, p=1.00). Likewise, no
significant effect of influenza vaccination was found for participants aged ≥65 years (n=88) on hospitalization or being symptomatic for either season (appendix pp. 2-3).

Discussion

In this study vaccination against influenza did not change the risk of hospitalization or symptoms due to COVID-19, and influenza vaccination was not associated with the risk of contracting SARS-CoV-2 infection as assessed by presence of antibodies against SARS-CoV-2.

To our knowledge this is the first large-scale study to examine the effect of influenza vaccination on severity of disease due to COVID-19 in HCW. Previous findings on non-specific, protective effects of influenza vaccination have been divergent[11–15]. One prior, cross-sectional registry study (n≈56million) by Huang et al. examined severity of COVID-19 as defined by the need for mechanical ventilation in patients aged ≥65 years[11]. When comparing influenza vaccinated individuals (n≈13million) to unvaccinated (n≈43million), Huang et al. found a 28% reduction in the odds (CI 0.68–0.76) of needing mechanical ventilation due to COVID-19 and a 24% reduction in the odds (CI 0.75–0.77) of SARS-CoV-2 infection. All baseline comorbidities except asthma (diabetes, hemoglobin disorder, immunocompromised, severe obesity and chronic kidney, lung, heart, and liver disease) were more frequent in the unvaccinated individuals and confounding is likely as no adjustment for comorbidity was performed. Furthermore, as Huang et al. examined influenza vaccination in patients aged ≥65 years, the population is not directly comparable to the current study. Our study focused on the working population and subgroup analyses of outcomes related to severity of disease included a sparse number of HCW aged ≥65 who had contracted SARS-CoV-2.

Noale et al. found influenza vaccination to reduce the probability of SARS-CoV-2 infection as measured by nasopharyngeal swab testing in a cross-sectional questionnaire study of participants aged <65 years (n=6,061, OR 0.85, CI 0.74–0.98), while no significant effect was found for participants aged ≥65 years (n=619, OR 0.87, CI 0.59–1.28)[12]. Several studies including 1900 to 11,000 participants did not find an effect of influenza vaccination on infection with SARS-CoV-2 as
measured by serology or nasopharyngeal swab testing for PCR[13–15]. The current study is in line with the previous null-effect studies on infection with SARS-CoV-2 as measured by pharyngeal swabs or serology. However, in some of the mentioned studies the outline of basic characteristics lacked a comparison of vaccinated to unvaccinated, and conclusions may be hampered as the participants were not randomized and the groups may not have been comparable[12,14,15].

This study has several limitations. As the information on severity of COVID-19 is based on a survey filled in by participants, contemporary hospitalizations may be underreported. Participants were, however, able to fill in the survey from home or at a later screening round. As for all observational studies confounding cannot be excluded. When it comes to influenza vaccination this issue may be of even higher susceptibility and importance as vaccination might be more frequent among individuals with a better health care insurance or higher awareness of personal health. Even though influenza vaccination in Denmark is offered to HCW free of charge and administered during work hours a higher proportion of educated HCW and HCW with chronic disease received the influenza vaccine.

In conclusion, the present findings indicate that influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19 disease.
Funding

This work was supported by an unrestricted grant by the Lundbeck Foundation [R349-2020-731]. The foundation had no influence on study design, data analysis, interpretation or publication.

Potential conflicts of interest. SRO, TKF, CTP, ES, HU, RD, AE, JHK, CSJ, OA, JR, MPH, RBH, SDN, FF, MEEM, IH, SBD, KF, JBN, LHH, PBN, RM, CAJJ and KKI declares no conflict of interest. HBU received lecture fee from BMS. FF received research grants from the Novo Nordisk Foundation and the Laerdal Foundation. MGB reports being an unpaid chairman at the Committee for Transfusion Medicine, Danish Society for Clinical Immunology. ADK received a research grant from the Danish Heart Foundation. TB reports grants for his institution from the Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, Kai Foundation, and Erik and Susanna Olesen’s Charitable Fund. TB reports an unrestricted grant for his institution and being on the advisory board for GSK; from Pfizer an unrestricted grant for his institution, being principal investigator for a clinical trial, and on advisory board; for Boehringer Ingelheim being principal investigator for a clinical trial; from Gilead Sciences an unrestricted grant for his institution, being principal investigator for a clinical trial and on advisory board; from MSD an unrestricted grant for his institution, being principal investigator and on advisory board; for Pentabase being board member; for Roche, Novartis and Kancera AB being principal investigator for clinical trials; for Janssen and Astra Zeneca being on the advisory board. TB received consulting fees from GSK and Pfizer. TB held lectures for GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, Abbvie and Astra Zeneca. TB received a donation of trial medication from Eli Lilly.
References

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021 Dec 6]. Available from: https://covid19.who.int/?gclid=EAIaIQobChMIwKmW19a_6QJvTOd3Ch1fAAXEAAAYASABgL1M_D_BwE

2. Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19. Med. Hypotheses. Churchill Livingstone; 2020.

3. Depoux A, Martin S, Karafillakis E, Preet R, Wilder-Smith A, Larson H. The pandemic of social media panic travels faster than the COVID-19 outbreak. J Travel Med [Internet]. Oxford University Press; 2020 [cited 2021 Dec 16]; 27(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107516/

4. Ansatte på offentlige sygehuse [Internet]. [cited 2021 Dec 20]. Available from: https://www.esundhed.dk/Emner/Beskaeftigede-i-sundhedsvaesnet/Ansatte-paa-offentlige-sygehuse

5. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42(2):377–381.

6. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform [Internet]. Academic Press Inc.; 2019 [cited 2020 Apr 25]; 95:103208. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1532046419301261

7. Harritshøj LH, Gybel-Brask M, Afzal S, et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol. American Society for Microbiology;
Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis [Internet]. Elsevier; 2020 [cited 2020 Aug 10]; . Available from: http://www.ncbi.nlm.nih.gov/pubmed/32758438

Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through six months: a Danish observational cohort study of 44,000 healthcare workers. Accept Awaiting Publ.

Hosmer-Lemeshow Test: Definition - Statistics How To [Internet]. [cited 2021 Dec 15]. Available from: https://www.statisticshowto.com/hosmer-lemeshow-test/

Huang K, Lin S-W, Sheng W-H, Wang C-C. Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States. Sci Reports 2021 111 [Internet]. Nature Publishing Group; 2021 [cited 2021 Aug 20]; 11(1):1–6. Available from: https://www.nature.com/articles/s41598-021-90068-y

Noale M, Trevisan C, Maggi S, et al. The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. Vaccines 2020, Vol 8, Page 471 [Internet]. Multidisciplinary Digital Publishing Institute; 2020 [cited 2021 Aug 23]; 8(3):471. Available from: https://www.mdpi.com/2076-393X/8/3/471/htm

Kissling E, Hooiveld M, Brytting M, et al. Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020. Influenza Other Respi Viruses [Internet]. John Wiley & Sons, Ltd; 2021 [cited 2021 Aug 23]; 15(4):429–438. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/irv.12839

Belingheri M, Paladino ME, Latocca R, Vito G De, Riva MA. Association between seasonal flu
vaccination and COVID-19 among healthcare workers. Occup Med (Chic Ill) [Internet]. Oxford Academic; 2020 [cited 2021 Aug 23]; 70(9):665–671. Available from: https://academic.oup.com/occmed/article/70/9/665/6029444

15. Martínez-Baz I, Trobajo-Sanmartín C, Arregui I, et al. Influenza vaccination and risk of sars-cov-2 infection in a cohort of health workers [Internet]. Vaccines. Multidisciplinary Digital Publishing Institute; 2020 [cited 2021 Aug 23]. p. 1–7. Available from: https://www.mdpi.com/2076-393X/8/4/611/htm
Table 1, baseline characteristics

|                          | Vaccinated | Not vaccinated | p    |
|--------------------------|------------|----------------|------|
| N                        | 13,702     | 32,410         |      |
| Female sex (%)           | 10,502 (76.6) | 26,518 (81.8) | <0.001 |
| Age (median [IQR])       | 46.71 [35.42, 57.70] | 44.69 [33.38, 54.39] | <0.001 |
| Body mass index (median [IQR]) | 24.22 [21.95, 27.34] | 24.22 [21.94, 27.46] | 0.270 |
| Ever smoker (%)           | 2,468 (18.1) | 7,188 (22.3) | <0.001 |
| Excess alcohol consumption^ (%) | 1,202 (8.8)  | 2,111 (6.6)  | <0.001 |
| Chronic lung disease (%)  | 1,578 (11.5) | 2,058 (6.3)  | <0.001 |
| Diabetes mellitus (%)     | 399 (2.9)   | 468 (1.4)     | <0.001 |
| Chronic heart disease (%) | 368 (2.7)   | 446 (1.4)     | <0.001 |
| Chronic kidney disease (%)| 46 (0.3)    | 64 (0.2)      | 0.007 |
| Impaired immune system (%)| 383 (2.8)   | 432 (1.3)     | <0.001 |
| Patient contact (%)       | 11,529 (84.3) | 27,575 (85.2) | 0.016 |
| Working at a dedicated COVID-19 ward (%) | 2,295 (16.7) | 4,876 (15.0) | <0.001 |
| Education level (%)       |              |                | <0.001 |
| No education or elementary school | 386 (2.8) | 1,202 (3.7) |
| High school               | 513 (3.8)   | 2,326 (7.2)   |      |
| Vocational education or bachelor’s degree | 7,299 (53.5) | 21,120 (65.6) |
| Master’s degree or higher | 5,434 (39.9) | 7,537 (23.4) |

Table is stratified according to the influenza vaccination in the season 2019/2020.

^ Excess alcohol consumption was defined as >14 units of alcohol for men and >7 units of alcohol for women per week (one unit corresponds roughly to one beer or glass of wine).
Table 2, study outcomes for influenza vaccinated participants compared with participants who did not receive the influenza vaccination

| The seasonal vaccination of 2018/2019 | Percentage unvaccinated with outcome (n) | Percentage vaccinated with outcome (n) | RR (95% CI) | aOR (95% CI) |
|----------------------------------------|------------------------------------------|----------------------------------------|------------|-------------|
| Presence of antibodies against SARS-CoV-2 | 6.54% (1,638/25,032) | 6.11% (570/9,334) | 0.93 (0.85-1.02) | 1.00 (0.90-1.10) |
| Symptomatic COVID-19 | 88.27% (2,100/2,379) | 90.27% (826/915) | 1.02 (1.00-1.05) | 1.16 (0.89-1.51) |
| Hospitalization due to COVID-19 | 1.51% (36/2,379) | 1.53% (14/915) | 1.01 (0.55-1.87) | 0.89 (0.47-1.70) |

| The seasonal vaccination of 2019/2020 | Percentage unvaccinated with outcome (n) | Percentage vaccinated with outcome (n) | RR (95% CI) | aOR (95% CI) |
|----------------------------------------|------------------------------------------|----------------------------------------|------------|-------------|
| Presence of antibodies against SARS-CoV-2 | 6.42% (1,544/24,060) | 6.50% (722/11,108) | 1.01 (0.93-1.10) | 1.06 (0.97-1.17) |
| Symptomatic COVID-19 | 87.96% (1,979/2,250) | 90.70% (1,024/1,129) | 1.03 (1.01-1.06) | 1.24 (0.97-1.59) |
| Hospitalization due to COVID-19 | 1.51% (34/2,250) | 1.51% (17/1,129) | 1.00 (0.56-1.78) | 0.91 (0.49-1.67) |

Outcomes for vaccinated compared with unvaccinated participants for the two seasonal vaccines. OR were adjusted for age ≥ 65 years, sex, ever smoker, unhealthy alcohol consumption as defined in table 1, diabetes, immune deficiency, lung-, heart-, or kidney disease, patient contact, working at COVID-19 wards, and educational level as defined in table 1.